Q3 FY2026
Filed Oct 30, 2026Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025; GAAP EPS increased 35% to $18.45 and non-GAAP EPS increased 70% to $20.07.
Total revenues grew 36%, led by a 68% increase in Sanofi collaboration revenue, while GAAP diluted EPS rose 35% and non-GAAP diluted EPS rose 70%. EYLEA HD U.S. sales, global Libtayo sales, and Dupixent global sales all grew, although EYLEA U.S. sales declined 41%.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 total revenuesGAAP | $5.12B | – | 36 % |
| Q3 2026 net product salesGAAP | $1.81B | – | 14 % |
| Q3 2026 collaboration revenueGAAP | $3.00B | – | – |
| Q3 2026 other revenueGAAP | $310M | – | 57 % |
| Q3 2026 income from operationsGAAP | $2.05B | – | – |
| Q3 2026 net incomeGAAP | $1.95B | – | 33 % |
| Q3 2026 net income per share - basicGAAP | $ 19.16 | – | – |
| Q3 2026 net income per share - dilutedGAAP | $ 18.45 | – | 35 % |
| Q3 2026 non-GAAP net incomenon-GAAP | $2.15B | – | 67 % |
| Q3 2026 non-GAAP net income per share - basicnon-GAAP | $ 21.14 | – | – |
| Q3 2026 non-GAAP net income per share - dilutednon-GAAP | $ 20.07 | – | 70 % |
| Q3 2026 research and developmentGAAP | $1.79B | – | 22 % |
| Q3 2026 research and developmentnon-GAAP | $1.65B | – | 23 % |
| Q3 2026 acquired in-process research and developmentGAAP | $21.5M | – | (73 %) |
| Q3 2026 selling, general, and administrativeGAAP | $677.8M | – | 3 % |
| Q3 2026 selling, general, and administrativenon-GAAP | $588.3M | – | 9 % |
| Q3 2026 cost of goods soldGAAP | $321.7M | – | 15 % |
| Q3 2026 cost of goods soldnon-GAAP | $245.7M | – | 8 % |
| Q3 2026 gross margin on net product salesGAAP | 82% | – | – |
| Q3 2026 gross margin on net product salesnon-GAAP | 86% | – | – |
| Q3 2026 cost of collaboration and contract manufacturingGAAP | $251.9M | – | 5 % |
| Q3 2026 effective tax rateGAAP | 14.7% | – | – |
| Q3 2026 effective tax ratenon-GAAP | 15.0% | – | – |
| Nine months ended September 30, 2026 total revenuesGAAP | $13.01B | – | – |
| Nine months ended September 30, 2026 net incomeGAAP | $3.97B | – | – |
| Nine months ended September 30, 2026 net income per share - dilutedGAAP | $ 37.37 | – | – |
| Nine months ended September 30, 2026 non-GAAP net incomenon-GAAP | $4.73B | – | – |
| Nine months ended September 30, 2026 non-GAAP net income per share - dilutednon-GAAP | $ 43.70 | – | – |
| Nine months ended September 30, 2026 gross margin on net product salesGAAP | 79% | – | – |
| Nine months ended September 30, 2026 gross margin on net product salesnon-GAAP | 86% | – | – |
| Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP | $3.68B | – | – |
| Nine months ended September 30, 2026 capital expendituresother | $771M | – | – |
| Nine months ended September 30, 2026 free cash flownon-GAAP | $2.90B | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| EYLEA HD - U.S.Higher sales volumes driven by increased demand, partly offset by a lower net selling price. | $699M | – | 62 % |
| EYLEA - U.S.Lower sales volumes resulting from continued competitive pressures and the continued transition of patients to EYLEA HD. | $400M | – | (41 %) |
| Total EYLEA HD and EYLEA - U.S.EYLEA HD growth was offset by lower EYLEA sales. | $1.10B | – | (1 %) |
| Libtayo - U.S.Higher sales volumes driven by increased demand. | $396M | – | 81 % |
| Libtayo - ROWNo driver quantified in the release. | $154M | – | 5 % |
| Total Libtayo - GlobalU.S. net product sales increased primarily due to higher sales volumes driven by increased demand. | $550M | – | 51 % |
| Praluent - U.S.No driver quantified in the release. | $ 81 | – | 21 % |
| Evkeeza - U.S.No driver quantified in the release. | $ 55 | – | 28 % |
| Lynozyfic - GlobalPercentage was not meaningful or greater than 100%. | $ 19 | – | – |
| Other products - GlobalPercentage was not meaningful or greater than 100%. | $ 1 | – | – |
| Sanofi collaboration revenueHigher share of profits from commercialization of antibodies, primarily associated with higher Dupixent sales, and the Sanofi Development Balance no longer reduced collaboration revenue. | $2.72B | – | 68 % |
| Bayer collaboration revenueNo driver quantified in the release. | $267M | – | (23 %) |
| Other collaboration revenueNo driver quantified in the release. | $ 10 | – | 67 % |
| Dupixent global net sales, recorded by SanofiHigher Dupixent sales contributed to higher Sanofi collaboration revenue. | $6.54B | – | 35 % |
| EYLEA HD global net salesU.S. demand-driven volume growth was partly offset by a lower net selling price. | $1.08B | – | 63 % |
| EYLEA global net salesContinued competitive pressures and the transition of patients to EYLEA HD. | $658.4M | – | (49 %) |
| Kevzara global net sales, recorded by SanofiNo driver quantified in the release. | $255.6M | – | 66 % |
Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.
Full year 2026 outlook
- Gross marginGAAP gross margin on net product sales: 78%–79%; non-GAAP gross margin on net product sales: 84%–85%
- Operating expensesGAAP R&D: $6.500–$6.635 billion; non-GAAP R&D: $5.950–$6.050 billion; GAAP SG&A: $2.830–$2.960 billion; non-GAAP SG&A: $2.500–$2.600 billion; GAAP COCM: $985 million–$1.035 billion; non-GAAP COCM: $970 million–$1.020 billion
- Tax rateGAAP effective tax rate: 13%–14%; non-GAAP effective tax rate: 14%–15%
- NoteCapital expenditures: $1.030–$1.100 billion
- NoteThe Company's 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release.
Capital returns
- During the nine months ended September 30, 2026, the Company repurchased $2.3 billion of its common stock.
- As of September 30, 2026, $2.2 billion remained available for share repurchases under the Company's share repurchase programs.
- In October 2026, the Company declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026.
What drove it
- Sanofi collaboration revenue rose as the Company's share of profits from commercialization of antibodies increased to $2.575 billion from $1.456 billion, primarily associated with higher Dupixent sales.
- The Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and no longer reduced Sanofi collaboration revenue beginning in the third quarter of 2026.
- GAAP and non-GAAP R&D increased due to clinical pipeline advancement and increased manufacturing activity associated with product candidates.
- The Company received an up-front payment of $1.0 billion under its expanded Sanofi antibody collaboration, to be recognized as collaboration revenue in the fourth quarter of 2026.
- Pasatru was approved by the FDA in August 2026 for adults with FOP.
Concerns
- EYLEA U.S. net product sales decreased due to continued competitive pressures and continued patient transition to EYLEA HD.
- Bayer collaboration revenue decreased 23%.
- GAAP gross margin on net product sales for the nine months ended September 30, 2026 was 79%, compared to 82% in the prior-year period; the reconciliation identified temporary manufacturing interruption-related costs of 3%.
- GAAP other income (expense), net decreased primarily due to lower net gains on marketable and other securities.
What to watch
- FDA target action date for cemdisiran in generalized myasthenia gravis is expected next month.
- The FDA target action date for Ordspono in relapsed or refractory diffuse large B-cell lymphoma is February 2027.
- The FDA target action date for the Libtayo alternative dosing schedule sBLA is March 2027.
- The Company plans to initiate a Phase 3 study in MASH/MASLD in the fourth quarter of 2026.
- The Company plans to report Phase 2 baloncibart results in POTS in November 2026 and plans to initiate a Phase 3 study in the first half of 2027, pending regulatory feedback.
- The $1.0 billion Sanofi up-front payment is expected to be recognized as collaboration revenue in the fourth quarter of 2026.
Balance sheet and cash flow
- Cash and marketable securities as of September 30, 2026: $ 18,858.5; December 31, 2025: $ 18,865.8.
- Long-term debt as of September 30, 2026: $ 1,987.0; December 31, 2025: $ 1,985.9.
- Accounts receivable, net as of September 30, 2026: $ 7,578.6; December 31, 2025: $ 5,741.1.
- Inventories as of September 30, 2026: $ 2,894.6; December 31, 2025: $ 3,200.8.
- Nine months ended September 30, 2026 net cash provided by operating activities: $ 3,675.3; capital expenditures: $ 771.0; free cash flow: $ 2,904.3.
Analysis
Regeneron reported a strong third quarter, with total revenues of $ 5,115.8 versus $ 3,754.3 in the third quarter of 2025. Collaboration revenue of $ 3,000.5 was the largest revenue stream and included $ 2,724.0 from Sanofi. Sanofi collaboration revenue benefited from higher profit sharing on antibody commercialization, primarily linked to higher Dupixent sales, and from the end of Sanofi Development Balance reductions beginning in the third quarter. Net product sales increased to $ 1,805.3 from $ 1,587.7.
Commercial performance reflected continued portfolio mix changes. EYLEA HD U.S. sales rose 62% to $ 699, supported by demand-driven volume gains, while EYLEA U.S. sales fell 41% to $ 400 amid competitive pressures and patient transitions to EYLEA HD. Combined U.S. EYLEA HD and EYLEA sales were $ 1,099, down 1%. Libtayo global sales increased 51% to $ 550, including 81% growth in U.S. sales to $ 396. Dupixent global net sales recorded by Sanofi increased 35% to $ 6,540.5.
Profitability expanded despite higher development spending. GAAP net income was $ 1,948.7 and non-GAAP net income was $ 2,150.0. GAAP diluted EPS was $ 18.45, while non-GAAP diluted EPS was $ 20.07. GAAP R&D increased to $ 1,794.7 and non-GAAP R&D increased to $ 1,653.8, with the release citing pipeline advancement and increased manufacturing activity. Third-quarter GAAP and non-GAAP gross margin on net product sales were unchanged at 82% and 86%, respectively.
Capital deployment included $2.3 billion of common-stock repurchases during the nine months ended September 30, 2026, with $2.2 billion remaining authorized at period end. The company declared a $0.94 per-share cash dividend in October. Cash and marketable securities were $ 18,858.5 and long-term debt was $ 1,987.0 as of September 30, 2026. Nine-month free cash flow was $ 2,904.3.
Full-year 2026 guidance calls for GAAP R&D of $6.500–$6.635 billion, non-GAAP R&D of $5.950–$6.050 billion, GAAP gross margin on net product sales of 78%–79%, and non-GAAP gross margin of 84%–85%. The company also expects capital expenditures of $1.030–$1.100 billion. The expanded Sanofi agreement produced a $1.0 billion up-front payment expected to be recognized as collaboration revenue in the fourth quarter of 2026, with potential additional milestones of up to $7.0 billion.
Management, verbatim
This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales.
Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron
Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported Q3 operating metrics were not provided.
- Quarterly operating cash flow and quarterly free cash flow were not provided.
- A full-year 2026 revenue guidance figure was not provided.
- Quarterly dividend cash amount and dividend payment history were not provided.
- Total debt beyond the reported long-term debt line was not provided.
- The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.